Maxim Group Downgrades Aridis Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Aridis’ Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action
Aridis Pharmaceuticals Inc’s (NASDAQ:ARDS) inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in…
Aridis Says Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective In Non-Human Primates
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that inhaled
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings (CCNB).
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers
Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.
91 Biggest Movers From Friday
Gainers
RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.